Nimacimab is under clinical development by Bird Rock Bio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Nimacimab’s likelihood of approval (LoA) and phase transition for Non-Alcoholic Steatohepatitis (NASH) took place on 04 May 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nimacimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Nimacimab overview

Nimacimab (RYI-018) is under development for the treatment of liver fibrosis including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease and metabolic disorders such as diabetic nephropathy (diabetic kidney disease). It is administered through intravenous and subcutaneous routes. The drug candidate is a negative allosteric modulating monoclonal antibody. It acts by targeting cannabinoid receptor-1 (CB-1). RYI-018 is developed by using RuiYi’s iCAPS platfrom (intermembranous conformation antigen presenting system). The drug candidate is a new molecular entity (NME).

Nimacimab (RYI-018) was under development for the treatment of diabetic nephropathy (diabetic kidney disease), diabetic gastroparesis, focal segmental glomerulosclerosis (FSGS) and immunoglobulin A (IgA) nephropathy.

Bird Rock Bio overview

Bird Rock Bio is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators and therapeutic antiobodies. The company offers pipeline products include Namacizumab, RYI-018 and Gerilimzumab. Its RYI-018 is a peripheral antagonist antibody to cannabinoid receptor 1 intended for the treatment of nonalcoholic steatohepatitis, fibrotic and metabolic diseases, and others. Bird Rock Bio’s Gerilimzumab is a novel anti IL-6 antibody indicated to treat rheumatoid arthritis, inflammatory and autoimmune diseases. The company partners with research institutes and pharmaceutical companies for its product development activities. Bird Rock Bio is headquartered in La Jolla, California, the US.

Quick View Nimacimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Nimacimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.